Contest Matchup #6: CRISPR Therapeutics vs Seres Therapeutics - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Contest Matchup #6: CRISPR Therapeutics vs Seres Therapeutics

Two biotech companies go head-to-head in our sixth Stockpicking matchup.

April 2, 2024

The battle of the biotech blockbusters. Which innovative drug developer is the better stock to choose in 2024?

Welcome to our 2024 Stockpicking competition! We are on a quest to find the best stock opportunities of the year for investors. Enter for free, with a chance to win a $1,000 Amazon gift card and a a free year of 7investing!

To complement our contest, we’ll be publishing seven head-to-head matchups between stocks; and we’ll include the winners in our own 7investing Team entry. At the bottom of each article is our voting poll, where you can help us determine which of these two companies will be the better-performer over the upcoming three-year period.

To following along with the event and to have all matchups sent directly to your Inbox, join our free email list:

Join 7investing's free email list

Our 6th Matchup: CRISPR Therapeutics vs Seres Therapeutics

Our sixth head-to-head matchup is between two biotech companies.

CRISPR Therapeutics (Nasdaq: CRSP) made history this past year when its newly-approved drug Casgevy became America’s first commercialized gene editing drug for the treatment of sickle cell disease.

Unlike chronic treatments from gene therapies — which require multiple doses over several years — Casgevy as a gene editing drug is a one-and-done cure. This has allowed it to command a price tag of a jaw-dropping $2 million. Yet insurers and America’s health system have both been happy to pay it, in order to replace decades of ongoing sickle cell treatment and care.

In partnership with Vertex Pharmaceuticals, CRISPR Therapeutics is on a mission to reduce its costs and broaden its distribution. There might soon be more of its gene editing drugs up for approval.

Seres Therapeutics (Nasdaq: MCRB) is a biotech pioneer as well.

As the world’s first publicly-traded microbiome company, it aims to restore the healthy balance of the gut after patients get exposed to nasty bacterial infections. Seres is focusing almost exclusively on commercializing its newly-approved drug VOWST, which treats C. difficile infection (“CDI”) in its second recurrence or later.

VOWST is already selling incredibly well and is receiving a strong reception from doctors. This might suggest that Seres’ stock might currently be vastly undervalued.

Will CRISPR Therapeutics or Seres Therapeutics be the more therapeutic investment for our 7investing portfolio on Stock Card? Cast your vote in our live poll below!

Join 7investing's Free Email List

Already a 7investing member? Log in here.